^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    cRAF inhibitor

    Related drugs:
    1m
    Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery (clinicaltrials.gov)
    P2, N=30, Completed, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Completed | Trial completion date: Aug 2024 --> Sep 2025 | Trial primary completion date: Mar 2024 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • Zepsun (donafenib)
    1m
    Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer (clinicaltrials.gov)
    P1, N=31, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation
    |
    everolimus • Avmapki (avutometinib) • Fakzynja (defactinib)
    1m
    Tissue-Agnostic Targeting in Solid Tumors: A PRISMA-Compliant Meta-Analysis of Efficacy, Safety, and Resistance Determinants Across Histologies. (PubMed, Oncol Res)
    In endometrial cancer, dostarlimab combined with chemotherapy improved PFS in both dMMR/MSI-H and mismatch repair-proficient disease and increased OS overall...Confidence is strongest for PD-1 inhibitors in MSI-H/dMMR tumors, trastuzumab deruxtecan in HER2-low or HER2-positive cancers, and encorafenib-based regimens in BRAF V600E metastatic colorectal cancer. Implementation should include validated assays (including reconfirmation of HER2 status), prioritize earlier treatment lines where gains are greatest, and require vigilant ILD monitoring. Head-to-head trials and assay standardization, especially for tumor mutational burden, remain priorities.
    Clinical • Retrospective data • Review • Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • Pan tumor
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    HER-2 positive • BRAF V600E • MSI-H/dMMR • BRAF V600
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Braftovi (encorafenib) • Jemperli (dostarlimab-gxly)
    2ms
    VS-6766-206: Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (2025-524713-88-00)
    P1/2, N=4, Not yet recruiting, Verastem Inc.
    New P1/2 trial
    |
    Avmapki (avutometinib) • Fakzynja (defactinib)
    2ms
    A Study of Avutometinib for People With Solid Tumor Cancers (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=23 --> 3
    Enrollment closed • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • NF1 (Neurofibromin 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
    |
    Avmapki (avutometinib) • Fakzynja (defactinib)
    2ms
    Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory (clinicaltrials.gov)
    P2, N=7, Terminated, Northwestern University | Trial completion date: Jul 2030 --> Apr 2026 | Active, not recruiting --> Terminated | Trial primary completion date: May 2026 --> Oct 2025; The study was closed due to accrual.
    Trial completion date • Trial termination • Trial primary completion date
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • Braftovi (encorafenib) • hydroxychloroquine
    2ms
    Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=45 --> 28 | Trial completion date: Jul 2028 --> Jun 2029 | Trial primary completion date: Apr 2028 --> May 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    BRAF mutation • BRAF V600
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    2ms
    Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer. (PubMed, Nature)
    BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization...dHuR abrogated BRAF expression by inducing its exon 18 skipping, and demonstrated superior suppression of BRAF-mutant CRC tumours including those gaining resistance to BRAF inhibitors. Finally, we performed kinome library CRISPR screening and revealed that inactivation of EGFR or MEK enhanced dHuR cytotoxicity, thus establishing a combinatorial strategy to treat patients with refractory BRAF-mutant CRC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • CRBN (Cereblon)
    |
    BRAF V600E • BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib)
    2ms
    BEAVER: Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • KIAA1549
    |
    BRAF mutation • BRAF V600K • BRAF fusion
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    2ms
    BECOME-MB: Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, UNICANCER | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K
    |
    Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    2ms
    Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | N=43 --> 7 | Trial primary completion date: Jul 2028 --> May 2026
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • Braftovi (encorafenib) • hydroxychloroquine
    2ms
    S2107: Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (clinicaltrials.gov)
    P2, N=86, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Sep 2026 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    BRAF V600E • BRAF V600
    |
    Opdivo (nivolumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • ABP 206 (nivolumab biosimilar)